ASCO Melanoma Spotlight

Evaluating Therapy With Encorafenib, Binimetinib, and Ribociclib in Melanoma

June 06, 2017

Paola A. Ascierto, MD, medical oncologist, director of Melanoma Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori “Fondazione G. Pascal,” discusses results of a phase Ib/II dose-escalation study evaluating triple combination therapy with encorafenib, binimetiinib, and ribociclib (Kisquali) in patients with BRAF V600 solid tumors and melanoma.

LAG-3 Antibody Combo Active in Patients With Immunotherapy-Treated Melanoma

June 06, 2017

More than half of patients with immunotherapy-relapsed/refractory melanoma benefited from treatment with nivolumab and an anti-lymphocyte activation gene-3 (LAG-3) antibody, according to data from an early clinical study.

Intracranial Response 58% With Dabrafenib/Trametinib Combination in BRAF V600 Melanoma

June 05, 2017

Dabrafenib (Tafinlar) plus trametinib (Mekinist) achieved an intracranial response (IR) rate of 58% in melanoma that has metastasized to the brain. The median duration of overall response (OR) of 6.5 months was generally shorter than that observed in melanoma patients without brain metastases. These initial findings from the phase II COMBI-MB trial were presented during an oral abstract session at the 2017 ASCO Annual Meeting.

Select GI AEs Managed in Studies of Nivolumab, Ipilimumab in Melanoma in Pooled Post-Hoc Analysis

June 05, 2017

Nivolumab (Opdivo) plus ipilimumab (Yervoy) or ipilimumab alone are associated with a high incidence of gastrointestinal (GI) toxicity, but most adverse events (AEs) are effectively managed using immunomodulators, which do not appear to inhibit tumor response. Additionally, nivolumab plus ipilimumab significantly improved overall survival (OS) and objective response rate (ORR) versus ipilimumab alone in patients with untreated advanced melanoma.

Immune Component May Affect Survival after Targeted Therapy for Melanoma

June 05, 2017

Overall survival in advanced melanoma treated with targeted therapy had a strong association with high PD-L1 expression and high levels of tumor infiltrating lymphocytes, analysis of tissue specimens from a randomized trial showed.

ORR Raised to 85% With Neoadjuvant, Adjuvant Dabrafenib/Trametinib Combo

June 04, 2017

Neoadjuvant and adjuvant dabrafenib (Tafinlar) plus trametinib (Mekinist) increased the overall response rate (ORR) to 85% in patients with high-risk resectable BRAF-mutant metastatic melanoma. And interestingly, the pathologic complete response (pCR) rate with the combination was 58%, as demonstrated in findings presented during the 2017 ASCO Annual Meeting.

Trial of Melanoma Triplet Combo Raises Questions

June 04, 2017

A 3-drug regimen for advanced melanoma led to objective responses in a majority of patients with advanced BRAF-mutant disease but also proved to be somewhat toxic, a small phase II study showed.

Five-Year OS Data for Dabrafenib/Trametinib Combo in Melanoma

June 04, 2017

Georgina V. Long, BSc, PhD, MBBS, professor of medical melanoma oncology, Melanoma Institute Australia, discusses 5-year overall survival data from a phase II trial of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF V600-mutant unresectable or metastatic melanoma during the 2017 ASCO Annual Meeting.

Pembrolizumab With Entinostat Led to Responses in Patients With Melanoma Who Progressed on Prior Checkpoint Inhibitors

June 04, 2017

Combining the PD-1 inhibitor pembrolizumab (Keytruda) with the HDAC inhibitor entinostat demonstrated promising clinical activity and acceptable safety in patients with melanoma who were refractory to immune checkpoint inhibitors.

Pembrolizumab/Ipilimumab Combo is Safe in Advanced Melanoma

June 15, 2016

A phase Ib expansion cohort of the Keynote-029 trial found that a combined regimen of pembrolizumab (Keytruda) at the standard dose (2 mg/kg) and ipilimumab (Yervoy) at a reduced dose (1 mg/kg) was safe and effective for patients with advanced melanoma.